Cite
HARVARD Citation
Tjokrowidjaja, A. et al. (2020). Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European journal of cancer. pp. 59-67. [Online].